Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer

Tannock, Ian F.; de Wit, Ronald; Berry, William R.; Horti, Jozsef; Pluzanska, Anna; Chi, Kim N.; Oudard, Stephane; Théodore, Christine; James, Nicholas D.; Turesson, Ingela; Rosenthal, Mark A.; Eisenberger, Mario A.

doi:10.1056/nejmoa040720

Cited by 5,735Prostate Cancer Treatment and ResearchBone health and treatmentsProstate Cancer Diagnosis and Treatment

Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer

Tannock, Ian F., de Wit, Ronald, Berry, William R., Horti, Jozsef, Pluzanska, Anna, Chi, Kim N., Oudard, Stephane, Théodore, Christine +4 more·2004·New England Journal of Medicine

DOI 10.1056/nejmoa040720

Open this paper in CoChat — free account

Abstract

BACKGROUND: Mitoxantrone plus prednisone reduces pain and improves the quality of life in men with advanced, hormone-refractory prostate cancer, but it does not improve survival. We compared such treatment with docetaxel plus prednisone in men with this disease. METHODS: From March 2000 through June 2002, 1006 men with metastatic hormone-refractory prostate cancer received 5 mg of prednisone twice daily and were randomly assigned to receive 12 mg of mitoxantrone per square meter of body-surface area every three weeks, 75 mg of docetaxel per square meter every three weeks, or 30 mg of docetaxel per square meter weekly for five of every six weeks. The primary end point was overall survival. Secondary end points were pain, prostate-specific antigen (PSA) levels, and the quality of life. All statistical comparisons were against mitoxantrone. RESULTS: As compared with the men in the mitoxantrone group, men in the group given docetaxel every three weeks had a hazard ratio for death of 0.76 (95 percent confidence interval, 0.62 to 0.94; P=0.009 by the stratified log-rank test) and those given weekly docetaxel had a hazard ratio for death of 0.91 (95 percent confidence interval, 0.75 to 1.11; P=0.36). The median survival was 16.5 months in the mitoxantrone group, 18.9 months in the group given docetaxel every 3 weeks, and 17.4 months in the group given weekly docetaxel. Among these three groups, 32 percent, 45 percent, and 48 percent of men, respectively, had at least a 50 percent decrease in the serum PSA level (P<0.001 for both comparisons with mitoxantrone); 22 percent, 35 percent (P=0.01), and 31 percent (P=0.08) had predefined reductions in pain; and 13 percent, 22 percent (P=0.009), and 23 percent (P=0.005) had improvements in the quality of life. Adverse events were also more common in the groups that received docetaxel. CONCLUSIONS: When given with prednisone, treatment with docetaxel every three weeks led to superior survival and improved rates of response in terms of pain, serum PSA level, and quality of life, as compared with mitoxantrone plus prednisone.

Integrity signals

Registry

Crossref · 10.1056/nejmoa040720

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Three nonhormonal systemic approaches prolong survival: docetaxel as first-line, cabazitaxel as second-line, and sipuleucel-T.
“Three nonhormonal systemic approaches have been found to prolong survival: docetaxel4 as first-line and cabazitaxel5 as second-line cytotoxic chemotherapy, and active cellular immunotherapy with sipuleucel-T.6”
From Abiraterone and Increased Survival in Metastatic Prostate Cancer (2011) · cites this paper as [4]

The McGill Pain Questionnaire: Major properties and scoring methods
Melzack, R. (1975) · Pain · doi:10.1016/0304-3959(75)90044-5 · Cited by 6,873 · see citing works
Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer
Petrylak, D. P., Tangen, C. M., Hussain, M., Lara, P. N., Jones, J. A., Taplin, M. E., Burch, P. A., Berry, D. L., Moinpour, C. M., Kohli, M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041318 · Cited by 3,665 · see citing works
A Randomized, Placebo-Controlled Trial of Zoledronic Acid in Patients With Hormone-Refractory Metastatic Prostate Carcinoma
Fred Saad, C., Gleason, D. M., Murray, R., Tchekmedyian, S., Venner, P. N., Lacombe, L., Chin, J. L., Vinholes, J., Goas, J. A., & Chen, B. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.19.1458 · Cited by 1,654 · see citing works
Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.
Tannock, I. F., Osoba, D., Stockler, M. R., Ernst, D. S., Neville, A. J., Moore, M. J., Armitage, G. R., Wilson, J. J., Venner, P. M., Coppin, C., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.6.1756 · Cited by 1,575 · see citing works
Self-citation
Hydrocortisone With or Without Mitoxantrone in Men With Hormone-Refractory Prostate Cancer: Results of the Cancer and Leukemia Group B 9182 Study
Kantoff, P. W., Halabi, S., Conaway, M. R., Picus, J., Kirshner, J., Hárs, V., Trump, D. L., Winer, E. P., & Vogelzang, N. J. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.8.2506 · Cited by 887 · see citing works
Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument
Esper, P., Mo, F., Chodak, G., Sinner, M., Cella, D., & Pienta, K. J. (1997) · Urology · doi:10.1016/s0090-4295(97)00459-7 · Cited by 696 · see citing works
Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response.
Tannock, I. F., Gospodarowicz, M., Meakin, W., Panzarella, T., Stewart, L., & Rider, W. D. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.5.590 · Cited by 407 · see citing works
Self-citation
Phase II Study of Docetaxel, Estramustine, and Low-Dose Hydrocortisone in Men With Hormone-Refractory Prostate Cancer: A Final Report of CALGB 9780
Savarese, D. M. F., Halabi, S., Hárs, V., Akerley, W., Taplin, M., Godley, P. A., Hussain, A., Small, E. J., & Vogelzang, N. J. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.9.2509 · Cited by 322 · see citing works
Weekly High-Dose Calcitriol and Docetaxel in Metastatic Androgen-Independent Prostate Cancer
Beer, T. M., Eilers, K. M., Garzotto, M. G., Egorin, M. J., Lowe, B. A., & Henner, W. D. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.117 · Cited by 253 · see citing works
Randomized, Double-Blind, Controlled Trial of Mitoxantrone/Prednisone and Clodronate Versus Mitoxantrone/Prednisone and Placebo in Patients With Hormone-Refractory Prostate Cancer and Pain
Ernst, D. S., Tannock, I. F., Winquist, E., Venner, P. M., Reyno, L. M., Moore, M. J., Chi, K. N., Ding, K., Elliott, C., & Parulekar, W. R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.03.042 · Cited by 246 · see citing works
Self-citation
Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: preliminary results.
Picus, J., & Schultz, M. (1999) · PubMed · Cited by 245 · see citing works
A Double-Blind, Placebo-Controlled, Randomized Trial of Oral Sodium Clodronate for Metastatic Prostate Cancer (MRC PR05 Trial)
Dearnaley, D. P. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djg038 · Cited by 236 · see citing works
Health-Related Quality of Life in Men With Metastatic Prostate Cancer Treated With Prednisone Alone or Mitoxantrone and Prednisone
Osoba, D., Tannock, I. F., Ernst, D. S., & Neville, A. J. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.6.1654 · Cited by 224 · see citing works
Self-citation
Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer
Beer, T. M., Pierce, W. C., Lowe, B. A., & Henner, W. D. (2001) · Annals of Oncology · doi:10.1023/a:1012258723075 · Cited by 193 · see citing works
Suramin Therapy for Patients With Symptomatic Hormone-Refractory Prostate Cancer: Results of a Randomized Phase III Trial Comparing Suramin Plus Hydrocortisone to Placebo Plus Hydrocortisone
Small, E. J., Meyer, M., Marshall, M. E., Reyno, L. M., Meyers, F. J., Natale, R. B., Lenehan, P. F., Chen, L., Slichenmyer, W. J., & Eisenberger, M. A. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.7.1440 · Cited by 187 · see citing works
Self-citation
Flutamide Versus Prednisone in Patients With Prostate Cancer Symptomatically Progressing After Androgen-Ablative Therapy: A Phase III Study of the European Organization for Research and Treatment of Cancer Genitourinary Group
Fosså, S. D., Slee, P. H. T. J., Brausi, M. A., Horenblas, S., Hall, R. R., Jw, H., Aaronson, N. K., de Prijck, L., & Collette, L. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.1.62 · Cited by 176 · see citing works
Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate
BERRY, W. (2001) · Seminars in Oncology · doi:10.1016/s0093-7754(01)90149-6 · Cited by 163 · see citing works
Self-citation
Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer.
Berry, W. R., Dakhil, S. R., Modiano, M., Gregurich, M., & Asmar, L. (2002) · PubMed · doi:10.1016/s0022-5347(05)64163-8 · Cited by 159 · see citing works
Self-citation
A phase II trial of docetaxel (Taxotere) in hormone-refractory prostate cancer: correlation of antitumor effect to phosphorylation of Bcl-2.
Friedland, D., Cohen, J., Miller, R., Voloshin, M., Gluckman, R. A., Lembersky, B. C., Zidar, B. L., Keating, M., Reilly, N., & Dimitt, B. (1999) · PubMed · Cited by 155 · see citing works
Current strategies in the management of hormone refractory prostate cancer
Martel, C. L., Gumerlock, P. H., Meyers, F. J., & Lara, P. N. (2003) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(02)00090-7 · Cited by 97 · see citing works
The antiandrogen withdrawal syndrome
Wirth, M. P., & Froschermaier, S. E. (1997) · Urological Research · doi:10.1007/bf00941991 · Cited by 72 · see citing works
STEROID HORMONE WITHDRAWAL SYNDROMES
Kelly, W. K., Slovin, S. F., & Scher, H. I. (1997) · Urologic Clinics of North America · doi:10.1016/s0094-0143(05)70389-x · Cited by 69 · see citing works
Chemotherapy for androgen-independent prostate cancer
Petrylak, D. P. (2002) · Seminars in Urologic Oncology · doi:10.1053/suro.2002.35052 · Cited by 62 · see citing works
DEXAMETHASONE DOES NOT SIGNIFICANTLY CONTRIBUTE TO THE RESPONSE RATE OF DOCETAXEL AND ESTRAMUSTINE IN ANDROGEN INDEPENDENT PROSTATE CANCER
Weitzman, A., Shelton, G., Zuech, N., Owen, C. E., Judge, T. W., Benson, M. C., Sawczuk, I. S., Katz, A. E., Olsson, C. A., Bagiella, E., et al. (2000) · The Journal of Urology · doi:10.1016/s0022-5347(05)67815-9 · Cited by 60 · see citing works
The impact of docetaxel, estramustine, and low dose hydrocortisone on the quality of life of men with hormone refractory prostate cancer and their partners: A feasibility study
Kornblith, A. B., Herndon, J. E., Zuckerman, E., Godley, P. A., Savarese, D. M. F., Vogelzang, N., & Holland, J. C. (2001) · Annals of Oncology · doi:10.1023/a:1011102619058 · Cited by 55 · see citing works
The potential role of bisphosphonates in prostate cancer
Oades, G. M., Coxon, J. P., & Colston, K. W. (2002) · Prostate Cancer and Prostatic Diseases · doi:10.1038/sj.pcan.4500607 · Cited by 51 · see citing works
A Model to Select Chemotherapy Regimens for Phase III Trials for Extensive-Stage Small-Cell Lung Cancer
Chen, T. T. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.19.1601 · Cited by 40 · see citing works

Flagged first, then by citations

1 of the 28 references couldn’t be matched to a known paper.

Sorted by citations

Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572 · see citing works
Abiraterone and Increased Survival in Metastatic Prostate Cancer
de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K. N., Jones, R. J., Goodman, O. B., Saad, F., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014618 · Cited by 4,407 · see citing works
“Arthralgia 215 (27) 33 (4) 0 89 (23) 16 (4) 0”
Self-citation
Senescence-Associated Secretory Phenotypes Reveal Cell-Nonautonomous Functions of Oncogenic RAS and the p53 Tumor Suppressor
Coppé, J.-P., Patil, C. K., Rodier, F., Sun, Y., Muñoz, D. P., Goldstein, J., Nelson, P. S., Desprez, P.-Y., & Campisi, J. (2008) · PLoS Biology · doi:10.1371/journal.pbio.0060301 · Cited by 302 · see citing works
“We thank R. Driver for support with the array experiments, J. Gray and R. Neve for discussions, cells, and use of Cellomix; A. Huang for help with the microdissection and PCR; A. Zielinski and J. Allison for technical help; T. Beer, M. Garzotto, C. Higano, L. True, R. Vessella, and the University of Washington Medical…”
BackgroundMethodInfluential
Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer
Petrylak, D. P., Tangen, C. M., Hussain, M., Lara, P. N., Jones, J. A., Taplin, M. E., Burch, P. A., Berry, D. L., Moinpour, C. M., Kohli, M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041318 · Cited by 3,665 · see citing works
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
Parker, C., Nilsson, S., Heinrich, D., Helle, S. I., O'Sullivan, J. M., Fosså, S. D., Chodacki, A., Wiechno, P., Logue, J., Seke, M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1213755 · Cited by 3,408 · see citing works
Self-citation
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
de Bono, J. S., Oudard, S., Ozguroglu, M., Hansen, S., Machiels, J.-P., Kocak, I., Gravis, G., Bodrogi, I., Mackenzie, M. J., Shen, L., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61389-x · Cited by 3,318 · see citing works
Self-citation
EAU Guidelines on Prostate Cancer
Heidenreich, A., Aus, G., Bolla, M., Joniau, S., Matveev, V. B., Schmid, H. P., & Zattoni, F. (2007) · European Urology · doi:10.1016/j.eururo.2007.09.002 · Cited by 3,134 · see citing works
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
Beer, T. M., Armstrong, A. J., Rathkopf, D. E., Loriot, Y., Sternberg, C. N., Higano, C. S., Iversen, P., Bhattacharya, S., Carles, J., Chowdhury, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1405095 · Cited by 3,028 · see citing works
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
Sweeney, C. J., Chen, Y., Carducci, M. A., Liu, G., Jarrard, D. F., Eisenberger, M. A., Wong, Y., Hahn, N. M., Kohli, M., Cooney, M. M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503747 · Cited by 2,908 · see citing works
Self-citation
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
Ryan, C. J., Smith, M. R., de Bono, J. S., Molina, A., Logothetis, C. J., de Souza, P., Fizazi, K., Mainwaring, P., Piulats, J. M., Ng, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209096 · Cited by 2,796 · see citing works
Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group
Scher, H. I., Halabi, S., Tannock, I. F., Morris, M. J., Sternberg, C. N., Carducci, M. A., Eisenberger, M. A., Higano, C. S., Bubley, G. J., Dreicer, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.4487 · Cited by 2,228 · see citing works
Self-citation
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
James, N. D., Sydes, M. R., Clarke, N. W., Mason, M. D., Dearnaley, D. P., Spears, M. R., Ritchie, A. W. S., Parker, C. C., Russell, J. M., Attard, G., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)01037-5 · Cited by 1,983 · see citing works
Self-citation
EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced, Relapsing, and Castration-Resistant Prostate Cancer
Heidenreich, A., Bastian, P. J., Joaquim Bellmunt, B., Bolla, M., Joniau, S., van der Kwast, T., Mason, M., Matveev, V., Wiegel, T., Zattoni, F., et al. (2013) · European Urology · doi:10.1016/j.eururo.2013.11.002 · Cited by 1,847 · see citing works
Abiraterone for prostate cancer not previously treated with hormone therapy
James, N. D., de Bono, J. S., Spears, M. R., Clarke, N. W., Mason, M. D., Dearnaley, D. P., Ritchie, A. W. S., Amos, C. L., Gilson, C., Jones, R. J., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1702900 · Cited by 1,801 · see citing works
Self-citation
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study.
Cohen, E., Soulières, D., le Tourneau, C., Dinis, J., Licitra, L., Ahn, M., Soria, A., Machiels, J., Mach, N., Mehra, R., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)31999-8 · Cited by 1,423 · see citing works
Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo
Farokhzad, O. C., Cheng, J., Teply, B. A., Sherifi, I., Jon, S., Kantoff, P. W., Richie, J. P., & Langer, R. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0601755103 · Cited by 1,667 · see citing works
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
Scher, H. I., Morris, M. J., Stadler, W. M., Higano, C. S., Basch, E., Fizazi, K. S., Antonarakis, E. S., Beer, T. M., Carducci, M. A., Chi, K. N., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.2702 · Cited by 1,665 · see citing works
Self-citation
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer
Davis, I. D., Martin, A. J., Stockler, M. R., Begbie, S., Chi, K. N., Chowdhury, S., Coskinas, X., Frydenberg, M., Hague, W. E., Horvath, L. G., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1903835 · Cited by 1,633 · see citing works
Self-citation
Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
Mohler, J. L., Antonarakis, E. S., Armstrong, A. J., D'Amico, A. V., Davis, B. J., Dorff, T. B., Eastham, J. A., Enke, C. A., Farrington, T. A., Higano, C. S., et al. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.0023 · Cited by 1,531 · see citing works
EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer
Cornford, P. A., Joaquim Bellmunt, B., Bolla, M., Briers, E., Santis, M. D., Gross, T., Henry, A. M., Joniau, S., Lam, T. B. L., Mason, M. D., et al. (2016) · European Urology · doi:10.1016/j.eururo.2016.08.002 · Cited by 1,440 · see citing works
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
Fizazi, K. S., Scher, H. I., Molina, A., Logothetis, C. J., Chi, K. N., Jones, R. J., Staffurth, J. N., North, S. A., Vogelzang, N. J., Fred Saad, C., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70379-0 · Cited by 1,376 · see citing works
Self-citation
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
Ryan, C. J., Smith, M. R., Fizazi, K., Saad, F., Mulders, P. F. A., Sternberg, C. N., Miller, K., Logothetis, C. J., Shore, N. D., Small, E. J., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71205-7 · Cited by 1,369 · see citing works
Risk of Prostate Cancer–Specific Mortality Following Biochemical Recurrence After Radical Prostatectomy
Freedland, S. J., Humphreys, E. B., Mangold, L. A., Eisenberger, M. A., Dorey, F. J., Walsh, P. C., & Partin, A. W. (2005) · JAMA · doi:10.1001/jama.294.4.433 · Cited by 1,362 · see citing works
Self-citation
Adjuvant Radiotherapy for Pathological T3N0M0 Prostate Cancer Significantly Reduces Risk of Metastases and Improves Survival: Long-Term Followup of a Randomized Clinical Trial
Thompson, I. M., Tangen, C. M., Paradelo, J. C., Lucia, M. S., Miller, G. J., Troyer, D. A., Messing, E. M., Forman, J. D., Chin, J. L., Swanson, G. P., et al. (2009) · The Journal of Urology · doi:10.1016/j.juro.2008.11.032 · Cited by 1,227 · see citing works
[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial
Hofman, M. S., Emmett, L., Sandhu, S., Iravani, A., Joshua, A. M., Goh, J. C., Pattison, D. A., Tan, T. H., Kirkwood, I. D., Ng, S., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00237-3 · Cited by 1,170 · see citing works
Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect
Maeda, H., Bharate, G. Y., & Daruwalla, J. (2008) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2008.11.010 · Cited by 1,171 · see citing works
Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer: Updated Survival in the TAX 327 Study
Berthold, D. R., Pond, G. R., Soban, F., de Wit, R., Eisenberger, M., & Tannock, I. F. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.4008 · Cited by 1,145 · see citing works
Self-citation
Prostate cancer
Rebello, R. J., Oing, C., Knudsen, K. E., Loeb, S., Johnson, D. C., Reiter, R. E., Gillessen, S., van der Kwast, T., & Bristow, R. G. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00243-0 · Cited by 1,157 · see citing works
Guideline for the Management of Clinically Localized Prostate Cancer: 2007 Update
Thompson, I. M., Thrasher, J. B., Aus, G., Burnett, A. L. “., Canby‐Hagino, E., Cookson, M. S., D'Amico, A. V., Dmochowski, R. R., Eton, D. T., Forman, J. D., et al. (2007) · The Journal of Urology · doi:10.1016/j.juro.2007.03.003 · Cited by 1,112 · see citing works
Placebo-Controlled Phase III Trial of Immunologic Therapy with Sipuleucel-T (APC8015) in Patients with Metastatic, Asymptomatic Hormone Refractory Prostate Cancer
Small, E. J., Schellhammer, P. F., Higano, C. S., Redfern, C. H., Nemunaitis, J. J., Valone, F. H., Verjee, S., Jones, L. A., & Hershberg, R. M. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.5252 · Cited by 1,108 · see citing works
EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II—2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer
Cornford, P. A., van den Bergh, R. C. N., Briers, E., den Broeck, T. V., Cumberbatch, M. G. K., Santis, M. D., Fanti, S., Fossati, N., Gandaglia, G., Gillessen, S., et al. (2020) · European Urology · doi:10.1016/j.eururo.2020.09.046 · Cited by 1,079 · see citing works
Biology of Progressive, Castration-Resistant Prostate Cancer: Directed Therapies Targeting the Androgen-Receptor Signaling Axis
Scher, H. I., & Sawyers, C. L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.4777 · Cited by 1,025 · see citing works
Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Parker, C., Castro, E., Fizazi, K., Heidenreich, A., Ost, P., Procopio, G., Tombal, B., & Gillessen, S. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.06.011 · Cited by 977 · see citing works
Androgen receptor: structure, role in prostate cancer and drug discovery
Tan, M.-H., Li, J., Xu, H. E., Melcher, K., & Yong, E. (2014) · Acta Pharmacologica Sinica · doi:10.1038/aps.2014.18 · Cited by 958 · see citing works
Molecular genetics of prostate cancer: new prospects for old challengesPreprint
Shen, M. M., & Abate-Shen, C. T. (2010) · Genes & Development · doi:10.1101/gad.1965810 · Cited by 949 · see citing works
External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study
Bolla, M., van Tienhoven, G., Warde, P. R., Dubois, J. B., Mirimanoff, R., Storme, G. A., Bernier, J., Kuten, A., Sternberg, C. N., Billiet, I., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70223-0 · Cited by 947 · see citing works
Prostate cancer
Attard, G., Parker, C. C., Eeles, R. A., Schröder, F. H., Tomlins, S. A., Tannock, I. F., Drake, C. G., & Bono, J. S. D. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61947-4 · Cited by 939 · see citing works
Self-citation
Androgen Receptor Regulates a Distinct Transcription Program in Androgen-Independent Prostate Cancer
Wang, Q., Li, W., Zhang, Y., Yuan, X., Xu, K., Yu, J., Chen, Z., Beroukhim, R., Wang, H., Lupien, M., et al. (2009) · Cell · doi:10.1016/j.cell.2009.04.056 · Cited by 897 · see citing works
Prostate Cancer
Mohler, J. L., Bahnson, R. R., Boston, B., Busby, J. E., D'Amico, A. V., Eastham, J. A., Enke, C. A., George, D., Horwitz, E. M., Huben, R. P., et al. (2010) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2010.0012 · Cited by 897 · see citing works
Guidelines on Prostate Cancer
Heidenreich, A., Joaquim Bellmunt, B., Bolla, M., Joniau, S., Matveev, V. B., Mottet, N., Wiegel, T., & Zattoni, F. (2013) · Cited by 869 · see citing works
A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)
Cherny, N. I., Sullivan, R., Dafni, U., Kerst, J. M., Sobrero, A., Zielinski, C., de Vries, E. G. E., & Piccart, M. J. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv249 · Cited by 818 · see citing works
Nanoparticles for drug delivery in cancer treatment
Haley, B., & Frenkel, E. P. (2008) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2007.03.015 · Cited by 805 · see citing works
PROVENGE (Sipuleucel-T) in Prostate Cancer: The First FDA-Approved Therapeutic Cancer Vaccine
Cheever, M. A., & Higano, C. S. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-3126 · Cited by 780 · see citing works
Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial
Gravis, G., Fizazi, K. S., Joly, F., Oudard, S. M., Priou, F., Esterni, B., Latorzeff, I., Delva, R., Krakowski, I., Laguerre, B., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70560-0 · Cited by 746 · see citing works
Self-citation
Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer
Kumar, A., Coleman, I. M., Morrissey, C. M., Zhang, X., True, L. D., Gulati, R., Etzioni, R., Bolouri, H., Montgomery, B., White, T. A., et al. (2016) · Nature Medicine · doi:10.1038/nm.4053 · Cited by 732 · see citing works
Treatment of Advanced Prostate Cancer
Teo, M. Y., Rathkopf, D. E., & Kantoff, P. W. (2019) · Annual Review of Medicine · doi:10.1146/annurev-med-051517-011947 · Cited by 738 · see citing works
Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer
de Wit, R., Bono, J. S. D., Sternberg, C. N., Fizazi, K. S., TOMBAL, B. F., Wülfing, C., Kramer, G., Eymard, J., Bamias, A., Carles, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911206 · Cited by 666 · see citing works
Self-citation
Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017
Gillessen, S., Attard, G., Beer, T. M., Beltran, H., Bossi, A., Bristow, R. G., Carver, B. S., Castellano, D., Chung, B. H., Clarke, N. W., et al. (2017) · European Urology · doi:10.1016/j.eururo.2017.06.002 · Cited by 645 · see citing works
Self-citation
Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer
Antonarakis, E. S., Lu, C., Luber, B. S., Wang, H., Chen, Y., Nakazawa, M., Nadal, R., Paller, C. J., Denmeade, S. R., Carducci, M. A., et al. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.1341 · Cited by 618 · see citing works
Self-citation
Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data
Scher, H. I., Jia, X., Bono, J. S. D., Fleisher, M., Pienta, K. J., Raghavan, D., & Heller, G. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70340-1 · Cited by 611 · see citing works
Prostate cancer
Sandhu, S. K., Moore, C. M., Chiong, E., Beltran, H., Bristow, R. G., & Williams, S. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00950-8 · Cited by 610 · see citing works
Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology
Schaeffer, E. M., Srinivas, S., Adra, N., An, Y., Barocas, D. A., Bitting, R. L., Bryce, A. H., Chapin, B. F., Cheng, H. H., D'Amico, A. V., et al. (2023) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2023.0050 · Cited by 613 · see citing works
Advancements and limitations in traditional anti-cancer therapies: a comprehensive review of surgery, chemotherapy, radiation therapy, and hormonal therapy
Zafar, A., Khatoon, S., Khan, M. J., Abu, J., & Naeem, A. (2025) · Discover Oncology · doi:10.1007/s12672-025-02198-8 · Cited by 601 · see citing works
Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Horwich, A., Parker, C. C., Bangma, C., & Kataja, V. V. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq174 · Cited by 602 · see citing works
Metastatic prostate cancer
Sartor, O., & de Bono, J. S. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1701695 · Cited by 546 · see citing works
Mechanisms of Androgen-Refractory Prostate Cancer
Debes, J. D., & Tindall, D. J. (2004) · New England Journal of Medicine · doi:10.1056/nejmp048178 · Cited by 558 · see citing works
Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study
Slovin, S. F., Higano, C. S., Hamid, O., Tejwani, S., Harzstark, A. L., Alumkal, J. J., Scher, H. I., Chin, K. M., Gagnier, P., McHenry, M. B., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt107 · Cited by 556 · see citing works
Initial Hormonal Management of Androgen-Sensitive Metastatic, Recurrent, or Progressive Prostate Cancer: 2007 Update of an American Society of Clinical Oncology Practice Guideline
Loblaw, D. A., Virgo, K. S., Nam, R. K., Somerfield, M. R., Ben‐Josef, E., Mendelson, D. S., Middleton, R., Sharp, S. A., Smith, T. J., Talcott, J. A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.1949 · Cited by 555 · see citing works
Mechanisms of resistance in castration-resistant prostate cancer (CRPC).
Chandrasekar, T., Yang, J. C., Gao, A. C., & Evans, C. P. (2015) · PubMed Central · doi:10.3978/j.issn.2223-4683.2015.05.02 · Cited by 531 · see citing works
Prostate Specific Antigen Best Practice Statement: 2009 Update
Greene, K. L., Albertsen, P. C., Babaian, R. J., Carter, H. B., Gann, P. H., Han, M., Kuban, D. A., Sartor, O. A., Stanford, J. L., Zietman, A. L., et al. (2009) · The Journal of Urology · doi:10.1016/j.juro.2009.07.093 · Cited by 516 · see citing works
Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial
Sartor, O. A., Coleman, R., Nilsson, S. F., Heinrich, D. A., Helle, S. I., O’Sullivan, J. M., Fosså, S. D., Chodacki, A., Wiechno, P., Logue, J. P., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70183-4 · Cited by 497 · see citing works
Self-citation
Natural History of Rising Serum Prostate-Specific Antigen in Men With Castrate Nonmetastatic Prostate Cancer
Smith, M. R., Kabbinavar, F. F., Fred Saad, C., Hussain, A., Gittelman, M., Bilhartz, D. L., Wynne, C., Murray, R. N., Zinner, N. R., Schulman, C., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.529 · Cited by 496 · see citing works
Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study
Nilsson, S. F., Franzén, L., Parker, C. C., Tyrrell, C., Blom, R., Tennvall, J., Lennernäs, B., Petersson, U., Johannessen, D. C., Sokal, M., et al. (2007) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70147-x · Cited by 493 · see citing works
EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced, Relapsing, and Castration-Resistant Prostate Cancer
Mottet, N., Joaquim Bellmunt, B., Bolla, M., Joniau, S., Mason, M. D., Matveev, V. B., Schmid, H., van der Kwast, T., Wiegel, T., Zattoni, F., et al. (2011) · European Urology · doi:10.1016/j.eururo.2011.01.025 · Cited by 492 · see citing works
Platinum-Based Chemotherapy for Variant Castrate-Resistant Prostate Cancer
Aparicio, A. M., Harzstark, A. L., Corn, P. G., Wen, S., Araujo, J. C., Tu, S., Pagliaro, L. C., Kim, J., Millikan, R. E., Ryan, C. J., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3791 · Cited by 482 · see citing works
Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer
Halabi, S., Kelly, W. K., Ma, H., Zhou, H., Solomon, N. C., Fizazi, K., Tangen, C. M., Rosenthal, M., Petrylak, D. P., Hussain, M., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.7270 · Cited by 461 · see citing works
Self-citation
Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial
Gravis, G., Boher, J., Joly, F., Soulie, M., Albiges, L. K., Priou, F., Latorzeff, I., Delva, R., Krakowski, I., Laguerre, B., et al. (2015) · European Urology · doi:10.1016/j.eururo.2015.11.005 · Cited by 458 · see citing works
Self-citation
Hormonal Therapy for Prostate Cancer
Desai, K. B., McManus, J. M., & Sharifi, N. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnab002 · Cited by 461 · see citing works
Update on systemic prostate cancer therapies: management of metastatic castration-resistant prostate cancer in the era of precision oncology
Nuhn, P., De Bono, J. S., Fizazi, K., Freedland, S. J., Grilli, M., Kantoff, P. W., Sonpavde, G., Sternberg, C. N., Yegnasubramanian, S., & Antonarakis, E. S. (2019) · European Urology · doi:10.1016/j.eururo.2018.03.028 · Cited by 437 · see citing works
Dual Roles of PARP-1 Promote Cancer Growth and Progression
Schiewer, M. J., Goodwin, J. F., Han, S., Brenner, J. C., Augello, M. A., Dean, J. L., Liu, F., Planck, J. L., Ravindranathan, P., Chinnaiyan, A. M., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0120 · Cited by 443 · see citing works
Mechanisms Underlying the Development of Androgen-Independent Prostate Cancer
Pienta, K. J., & Bradley, D. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0067 · Cited by 430 · see citing works
Taxane-Induced Blockade to Nuclear Accumulation of the Androgen Receptor Predicts Clinical Responses in Metastatic Prostate Cancer
Darshan, M. S., Loftus, M. S., Thadani‐Mulero, M., Levy, B. P., Escuín, D., Zhou, X. K., Gjyrezi, A., Chanel‐Vos, C., Shen, R., Tagawa, S. T., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1417 · Cited by 429 · see citing works
Androgen receptors in hormone-dependent and castration-resistant prostate cancer
Shafi, A. A., Yen, A. E., & Weigel, N. L. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.07.003 · Cited by 422 · see citing works
Survival with Newly Diagnosed Metastatic Prostate Cancer in the “Docetaxel Era”: Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019)
James, N. D., Spears, M. R., Clarke, N. W., Dearnaley, D. P., Bono, J. S. D., Gale, J., Jw, H., Hoskin, P., Jones, R. J., Laing, R. W., et al. (2014) · European Urology · doi:10.1016/j.eururo.2014.09.032 · Cited by 423 · see citing works
Self-citation
Prostate cancer
Damber, J., & Aus, G. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60729-1 · Cited by 418 · see citing works
Suppression of Acquired Docetaxel Resistance in Prostate Cancer through Depletion of Notch- and Hedgehog-Dependent Tumor-Initiating Cells
Domenech, J. M. D., Vidal, S. J., Rodríguez-Bravo, V., Castillo-Martín, M., Quinn, S. A., Barrueco, R. R., Bonal, D. M., Charytonowicz, E., Gladoun, N., de la Iglesia-Vicente, J., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.07.016 · Cited by 416 · see citing works
Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Parker, C. C., Gillessen, S., Heidenreich, A., & Horwich, A. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv222 · Cited by 416 · see citing works
Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer
Pienta, K. J., Machiels, J.-P., Schrijvers, D. L. A. L., Alekseev, B. Y., Shkolnik, M. I., Crabb, S. J., Li, S., Seetharam, S., Puchalski, T. A., Takimoto, C. H. M., et al. (2012) · Investigational New Drugs · doi:10.1007/s10637-012-9869-8 · Cited by 413 · see citing works
NCCN Task Force Report: Bone Health in Cancer Care
Gralow, J. R., Biermann, J. S., Farooki, A., Fornier, M. N., Gagel, R. F., Kumar, R., Litsas, G., McKay, R. R., Podoloff, D. A., Srinivas, S., et al. (2013) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2013.0215 · Cited by 411 · see citing works
Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial
Hoskin, P., Sartor, O. A., O’Sullivan, J. M., Johannessen, D. C., Helle, S. I., Logue, J. P., Bottomley, D., Nilsson, S. F., Vogelzang, N. J., Fang, F., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70474-7 · Cited by 409 · see citing works
Standardizing Patient-Reported Outcomes Assessment in Cancer Clinical Trials: A Patient-Reported Outcomes Measurement Information System Initiative
Garcia, S. F., Cella, D., Clauser, S. B., Flynn, K. E., Lad, T., Lai, J.-S., Reeve, B. B., Wilder Smith, A., Stone, A. A., & Weinfurt, K. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.2341 · Cited by 407 · see citing works
Significant and Sustained Antitumor Activity in Post-Docetaxel, Castration-Resistant Prostate Cancer With the CYP17 Inhibitor Abiraterone Acetate
Reid, A. H. M., Attard, G., Danila, D. C., Oommen, N. B., Olmos, D., Fong, P. C., Molife, L. R., Hunt, J., Messiou, C., Parker, C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.6819 · Cited by 394 · see citing works
Phase I Clinical Trial of the CYP17 Inhibitor Abiraterone Acetate Demonstrating Clinical Activity in Patients With Castration-Resistant Prostate Cancer Who Received Prior Ketoconazole Therapy
Ryan, C. J., Smith, M. R., Fong, L., Rosenberg, J. E., Kantoff, P., Raynaud, F., Martins, V., Lee, G., Kheoh, T., Kim, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.1281 · Cited by 396 · see citing works
Targeting the androgen receptor pathway in prostate cancer
Chen, Y., Sawyers, C. L., & Scher, H. I. (2008) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2008.07.005 · Cited by 393 · see citing works
Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies
Moilanen, A., Riikonen, R., Oksala, R., Ravanti, L., Aho, E., Wohlfahrt, G., Nykänen, P., Törmäkangas, O. P., Palvimo, J. J., & Kallio, P. J. (2015) · Scientific Reports · doi:10.1038/srep12007 · Cited by 383 · see citing works
Loss of Kelch-Like ECH-Associated Protein 1 Function in Prostate Cancer Cells Causes Chemoresistance and Radioresistance and Promotes Tumor Growth
Zhang, P., Singh, A., Yegnasubramanian, S., Esopi, D., Kombairaju, P., Bodas, M., Wu, H., Bova, G. S., & Biswal, S. S. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0589 · Cited by 376 · see citing works
Targeting the PI3K/AKT Pathway for the Treatment of Prostate Cancer
Sarker, D., Reid, A. H. M., Yap, T. A., & de Bono, J. S. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0125 · Cited by 366 · see citing works
177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial
Morris, M. J., Castellano, D., Herrmann, K., de Bono, J. S., Shore, N. D., Chi, K. N., Crosby, M., Piulats, J. M., Fléchon, A., Wei, X. X., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01653-2 · Cited by 362 · see citing works
Self-citation
A Contemporary Prognostic Nomogram for Men with Hormone-Refractory Metastatic Prostate Cancer: A TAX327 Study Analysis
Armstrong, A. J., Garrett-Mayer, E. S., Yang, Y.-C. O., de Wit, R., Tannock, I. F., & Eisenberger, M. A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1036 · Cited by 359 · see citing works
Self-citation
Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial
van den Eertwegh, A. J. M., Versluis, J., van den Berg, H. P., Santegoets, S. J. A. M., van Moorselaar, R. J. A., van der Sluis, T. M., Gall, H. E., Harding, T. C., Jooss, K. U., Lowy, I., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70007-4 · Cited by 355 · see citing works
Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial—FIRSTANA
Oudard, S. M., Fizazi, K. S., Sengeløv, L., Daugaard, G., Fred Saad, C., Hansen, S., Hjälm-Eriksson, M., Jassem, J., Thiery-Vuillemin, A., Caffo, O., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.72.1068 · Cited by 357 · see citing works
Self-citation
Tubulin-Targeting Chemotherapy Impairs Androgen Receptor Activity in Prostate Cancer
Zhu, M.-L., Horbinski, C. M., Garzotto, M., Qian, D. Z., Beer, T. M., & Kyprianou, N. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0585 · Cited by 352 · see citing works
EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II—2024 Update: Treatment of Relapsing and Metastatic Prostate Cancer
Tilki, D., van den Bergh, R. C. N., Briers, E., den Broeck, T. V., Brunckhorst, O., Darraugh, J., Eberli, D., Meerleer, G. D., Santis, M. D., Farolfi, A., et al. (2024) · European Urology · doi:10.1016/j.eururo.2024.04.010 · Cited by 394 · see citing works
Prostate Cancer Stem Cells: A New Target for Therapy
Maitland, N. J., & Collins, A. T. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.1472 · Cited by 349 · see citing works
Recommended Patient-Reported Core Set of Symptoms to Measure in Adult Cancer Treatment Trials
Reeve, B. B., Mitchell, S. A., Dueck, A. C., Basch, E., Cella, D. F., Reilly, C. M., Minasian, L. M., Denicoff, A. M., O’Mara, A. M., Fisch, M. J., et al. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju129 · Cited by 350 · see citing works
Prostate cancer as a model for tumour immunotherapy
Drake, C. G. (2010) · Nature reviews. Immunology · doi:10.1038/nri2817 · Cited by 348 · see citing works
Once-a-Week Versus Once-Every-3-Weeks Cisplatin Chemoradiation for Locally Advanced Head and Neck Cancer: A Phase III Randomized Noninferiority Trial
Noronha, V., Joshi, A., Patil, V., Agarwal, J., Laskar, S. G., Budrukkar, A. N., Murthy, V., Gupta, T., Dcruz, A. K., Banavali, S. D., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.9457 · Cited by 346 · see citing works
GADD45 Proteins: Central Players in Tumorigenesis
Tamura, R. E., de Vasconcellos, J. F., Sarkar, D., Libermann, T. A., Fisher, P. B., & Zerbini, L. F. (2012) · Current Molecular Medicine · doi:10.2174/156652412800619978 · Cited by 337 · see citing works
Multinational, Double-Blind, Phase III Study of Prednisone and Either Satraplatin or Placebo in Patients With Castrate-Refractory Prostate Cancer Progressing After Prior Chemotherapy: The SPARC Trial
Sternberg, C. N., Petrylak, D. P., Sartor, O. A., Witjes, J. A., Demkow, T., Ferrero, J.-., Eymard, J., Falcon, S. G., Calabrò, F., James, N. D., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.1228 · Cited by 340 · see citing works
Self-citation
Risk of Prostate Cancer-Specific Mortality Following Biochemical Recurrence After Radical Prostatectomy
Freedland, S. J., Humphreys, E. B., Mangold, L. A., Eisenberger, M., Dorey, F. J., Walsh, P. C., & Partin, A. W. (2006) · The Journal of Urology · doi:10.1016/s0022-5347(05)00388-5 · Cited by 339 · see citing works
Self-citation

Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer
Petrylak, D. P., Tangen, C. M., Hussain, M., Lara, P. N., Jones, J. A., Taplin, M. E., Burch, P. A., Berry, D. L., Moinpour, C. M., Kohli, M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041318 · Cited by 3,665 · see citing works
Docetaxel plus prednisone improves survival in men with advanced prostate cancer☆, ☆☆, ☆☆☆Abstracted from: Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502–12.
Shelley, M. D., & Mason, M. D. (2005) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2005.05.003 · Cited by 13 · see citing works
A systematic review of the effectiveness of docetaxel and mitoxantrone for the treatment of metastatic hormone-refractory prostate cancer
Collins, R., Trowman, R., Norman, G., Light, K., Birtle, A. J., Fenwick, E. A. L., Palmer, S., & Riemsma, R. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603287 · Cited by 23 · see citing works
Docetaxel versus mitoxantrone in men with hormone-refractory prostate cancer
(2008) · Nature Clinical Practice Oncology · doi:10.1038/ncponc1115
Does docetaxel plus prednisone prolong the survival of men with metastatic hormone-refractory prostate cancer?
Sternberg, C. N. (2005) · Nature Clinical Practice Urology · doi:10.1038/ncpuro0066

Authors: Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., Oudard, S., Théodore, C., James, N. D., Turesson, I., Rosenthal, M. A., & Eisenberger, M. A.
Affiliations: University of Toronto (CA)
National Institute of Oncology (HU)
Medical University of Lodz (PL)
BC Cancer Agency (CA)
Institut Gustave Roussy (FR)
Cancer Research UK (GB)
Uppsala University Hospital (SE)
Cancer Trials Australia (AU)
Johns Hopkins University (US)
ORCID: Tannock, Ian F.
Chi, Kim N.
James, Nicholas D.
Turesson, Ingela
Rosenthal, Mark A.
Eisenberger, Mario A.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2004-10-07
Volume: 351
Issue: 15
Pages: 1502-1512
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa040720
OpenAlex: W2120292596
Cited by: 5,735
References: 28
Citations by year: 2026: 97 · 2025: 132 · 2024: 191 · 2023: 172 · 2022: 226 · 2021: 273 · 2020: 267 · 2019: 243 · 2018: 277 · 2017: 278 · 2016: 323 · 2015: 337 · 2014: 342 · 2013: 370 · 2012: 392
FWCI: 187.05
Type: journal article
Language: en
Open access: closed
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Prostate Cancer Treatment and Research
Health Sciences › Medicine › Oncology › Bone health and treatments
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Prostate Cancer Diagnosis and Treatment
Keywords: docetaxel, mitoxantrone, prednisone, castration-resistant prostate cancer, metastatic prostate cancer, overall survival, prostate-specific antigen, pain, quality of life, chemotherapy schedule, adverse events, corticosteroids, androgen deprivation therapy, taxanes, anthracyclines, randomized trial comparison, treatment-related morbidity
MeSH terms: Docetaxel, Adenocarcinoma, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Follow-Up Studies, Humans, Male, Middle Aged, Mitoxantrone, Prednisone, Prostatic Neoplasms, Quality of Life, Survival Analysis, Drug Resistance, Neoplasm, Taxoids

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Cites

Cited by

Related

Record

About these checks